A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796 ·Status: COMPLETED ·Phase: PHASE1

A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

NCT05775887 ·Status: COMPLETED ·Phase: PHASE1

A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT07205796 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373485 ·Status: COMPLETED ·Phase: PHASE1

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

NCT05995275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Sequential Enhanced Safety Study of a Novel Coronavirus Messenger RNA (mRNA) Vaccine in Adults Aged 18 Years and Older.

NCT05568693 ·Status: UNKNOWN ·Phase: NA

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

NCT05345873 ·Status: UNKNOWN ·Phase: PHASE2

A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers

NCT01081691 ·Status: COMPLETED ·Phase: PHASE1

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04678830 ·Status: COMPLETED ·Phase: PHASE2

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT05373472 ·Status: COMPLETED ·Phase: PHASE2

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

NCT05279365 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT06585241 ·Status: RECRUITING ·Phase: PHASE4

Study of Ameliorating Effect of COVID-19 mRNA Vaccine in Individuals Immunized With Inactivated Vaccine

NCT04944381 ·Status: UNKNOWN ·Phase: NA

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

NCT05385991 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

NCT05886790 ·Status: UNKNOWN ·Phase: NA

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

NCT05272605 ·Status: COMPLETED ·Phase: PHASE1

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

NCT03001297 ·Status: COMPLETED ·Phase: PHASE1

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

NCT05038618 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

NCT04283461 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY3819253 (LY-CoV555) in Healthy Participants

NCT04537910 ·Status: COMPLETED ·Phase: PHASE1

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

NCT04495933 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

NCT03829384 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

NCT04785144 ·Status: COMPLETED ·Phase: PHASE1